Publications by authors named "S R Indraccolo"
Background: Mitochondrial DNA (mtDNA) pathogenic variants have been reported in several solid tumors including ovarian cancer (OC), the most lethal gynecologic malignancy, and raised interest as they potentially induce mitochondrial dysfunction and rewiring of cellular metabolism. Despite advances in recent years, functional characterization of mtDNA variants in cancer and their possible modulation of drug response remain largely uncharted.
Methods: Here, we characterized mtDNA variants in OC patient derived xenografts (PDX) and investigated their impact on cancer cells at multiple levels.
Article Synopsis
- In ovarian cancer, a comprehensive study examined various metabolism-related markers to understand their prognostic value, but results showed mixed outcomes in large patient groups.
- The study used advanced techniques on tissue samples from over 300 patients to analyze markers tied to glycolysis, glutamine metabolism, and hypoxia, but found that only one marker (GLS) hinted at a connection to patient survival, which was not statistically significant after adjustments.
- Ultimately, the research highlights the diversity of metabolism markers in ovarian cancer and suggests their expression patterns may still be relevant for future drug development, even if they don't currently correlate with treatment outcomes.
High heterogeneity in clinical benefit characterizes the use of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). We prospectively enrolled 113 advanced NSCLC patients treated with ICIs and performed liquid biopsy at the time of ICI start (T1), after 3 weeks (T2) and at the time of radiological evaluation (T3). Molecular variables were associated with outcome endpoints: cfDNA quantification, its dynamic change (∆T2-T1), variant allele frequency (VAF) of the gene with the highest frequency detected at baseline with NGS (maxVAF) and its dynamic change (∆T2-T1).
View Article and Find Full Text PDF